cervical cancer
Conditions
Interventions
experimental group:Moderately hypofractionated online adaptive radiotherapy.
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Patients must be fully voluntary and autonomous, having signed an informed consent form within 30 days prior to enrollment; 2.Aged >=18 years and <=75 years; 3.FIGO stage IB-IIIB cervical cancer; IIIC1 (lymph node metastasis <=2 cm, without common iliac lymph node metastasis; 4.Pathologically diagnosed as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; 5.Concurrent weekly cisplatin ± immunotherapy; 6.Able to undergo brachytherapy; 7.ECOG performance status of 0-1, with an expected ability to tolerate lying flat for half an hour.
Exclusion criteria
Exclusion criteria: 1.Patients who have undergone cervical cancer surgery, excluding pelvic lymphadenectomy/lymph node dissection or cervical conization; 2.FIGO stage IA, IIIC2, IVA, or IVB; 3.FIGO stage IIIC1 with lymph nodes >2 cm or common iliac lymph node metastasis; 4.History of previous abdominal or pelvic radiotherapy; 5.Pregnant or breastfeeding women; 6.Active infection with fever; 7.Other severe diseases that may significantly affect compliance with the clinical trial, such as unstable heart disease requiring treatment, kidney disease, chronic hepatitis, poorly controlled diabetes, or mental illness;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Complete Response;Overall Survival;Disease-Free Survival;Local Control Rate;Acute or chronic side effects;Quality of Life;Treatment cost; | — |
Countries
China
Contacts
Public ContactFuquan Zhang
Peking Union Medical College Hospital
Outcome results
None listed